KLRA Kailera Therapeutics, Inc.
$12.65▼ -0.94%
Healthcare
Other
Volume 29.8K
Avg Volume (10D) 1.16M
Key Metrics & Fundamentals
Market Cap
$1.64B
P/E Ratio
–
Div Yield
0.00%
52W Range
9.76 - 28.23
% vs 50 MA
-6.65%
% vs 200 MA
–%
RSI-14
53.1
MACD Histogram
+0.4100
Beta (1Y vs SPY)
0.96
Free Cash Flow
-$77.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$121.27M
COGS
–
Operating Exp
$121.37M
Operating Income
-$121.37M
EBIT
-$121.37M
Pretax Income
-$111.31M
Net Income
-$111.31M
EPS (Diluted)
-1.09
Price & Volume History
Loading chart…
Recent News
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
GlobeNewswire · Oct 20, 2026 4:01 PM ET
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
GlobeNewswire · Oct 1, 2026 6:45 AM ET
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Motley Fool · Sep 30, 2026 7:30 PM ET
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
MT Newswires · Sep 30, 2026 7:44 AM ET
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
GlobeNewswire · Sep 30, 2026 7:00 AM ET
Kailera Therapeutics to Participate in September Investor Conferences
GlobeNewswire · Sep 16, 2026 7:00 AM ET
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
Insider Monkey · Sep 15, 2026 12:16 AM ET
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
24/7 Wall St. · Aug 18, 2026 10:10 AM ET
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
Simply Wall St. · Aug 17, 2026 9:10 AM ET
2 GLP-1 Stocks That Could Double Your Money by 2031
Motley Fool · Aug 16, 2026 4:20 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KLRA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.